Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSPSILVA, Pedro G. M.NASCIMENTO, Charlene Troiani doPEDROSA, Rodrigo PintoNAKAZONE, Marcelo ArrudaNASCIMENTO, Michel Ulloffo doMELO, Leiliandry de AraujoJUNIOR, Osvaldo Lourenco SilvaZIMMERMANN, Sergio LuizMELO, Rodrigo Morel Vieira deBERGO, Ricardo ReinaldoPRECOMA, Dalton BertolimTRAMUJAS, LucasLIMA, Eduardo GomesDANTAS, Joao Miguel MaltaBARUZZI, Antonio Claudio do AmaralFLUMIGNAN, Ronald Luiz GomesPAIVA, Maria Sanali Moura de OliveiraGOWDAK, Luis Henrique WolffCARVALHO, Priscila Nasser deFIGUEIREDO NETO, Jose Albuquerque deSILVESTRE, Odilson MarcosFIORANELLI, AlexandreVIEIRA, Ricardo D. 'OliveiraHORAK, Ana Clara PeneluppiMIYADA, Debora Harumi KodamaKOJIMA, Flavia Cristina SoaresOLIVEIRA, Julia Souza deSILVA, Leila de OliveiraPAVANELLO, RicardoRAMACCIOTTI, EduardoLOPES, Renato D.NASCIMENTO, Charlene Troiani doPEDROSA, Rodrigo PintoNAKAZONE, Marcelo ArrudaNASCIMENTO, Michel Ulloffo doMELO, Leiliandry de AraujoJUNIOR, Osvaldo Lourenco SilvaZIMMERMANN, Sergio LuizMELO, Rodrigo Morel Vieira deBERGO, Ricardo ReinaldoPRECOMA, Dalton BertolimTRAMUJAS, LucasDANTAS, Joao Miguel MaltaBARUZZI, Antonio Claudio do AmaralFLUMIGNAN, Ronald Luiz GomesPAIVA, Maria Sanali Moura de OliveiraCARVALHO, Priscila Nasser deFIGUEIREDO NETO, Jose Albuquerque deSILVESTRE, Odilson MarcosFIORANELLI, AlexandreVIEIRA, Ricardo D. 'OliveiraFORTES, Jose Augusto RibasRITT, Luiz Eduardo FontelesREQUIAO-MOURA, Lucio R.BORGES, Fabricio AssamiBERNOCHE, ClaudiaPOMPILIO, Mauricio Antonio2024-04-052024-04-052024SCIENTIFIC REPORTS, v.14, n.1, article ID 4222, 10p, 20242045-2322https://observatorio.fm.usp.br/handle/OPI/59286There is limited contemporary prospective real-world evidence of patients with chronic arterial disease in Latin America. The Network to control atherothrombosis (NEAT) registry is a national prospective observational study of patients with known coronary (CAD) and/or peripheral arterial disease (PAD) in Brazil. A total of 2,005 patients were enrolled among 25 sites from September 2020 to March 2022. Patient characteristics, medications and laboratorial data were collected. Primary objective was to assess the proportion of patients who, at the initial visit, were in accordance with good medical practices (domains) for reducing cardiovascular risk in atherothrombotic disease. From the total of patients enrolled, 2 were excluded since they did not meet eligibility criteria. Among the 2,003 subjects included in the analysis, 55.6% had isolated CAD, 28.7% exclusive PAD and 15.7% had both diagnoses. Overall mean age was 66.3 (+/- 10.5) years and 65.7% were male patients. Regarding evidence-based therapies (EBTs), 4% were not using any antithrombotic drug and only 1.5% were using vascular dose of rivaroxaban (2.5 mg bid). Only 0.3% of the patients satisfied all the domains of secondary prevention, including prescription of EBTs and targets of body-mass index, blood pressure, LDL-cholesterol, and adherence of lifestyle recommendations. The main barrier for prescription of EBTs was medical judgement. Our findings highlight that the contemporary practice does not reflect a comprehensive approach for secondary prevention and had very low incorporation of new therapies in Brazil. Large-scale populational interventions addressing these gaps are warranted to improve the use of evidence-based therapies and reduce the burden of atherothrombotic disease.ClinicalTrials.gov NCT04677725engrestrictedAccessCardiovascular diseasesGuideline adherenceRegistriesrisk-factorsmortalityarticleCopyright NATURE PORTFOLIO10.1038/s41598-024-54516-9Multidisciplinary Sciences